Accumulation of murine amyloid-β mimics early Alzheimer's disease

Brain

Volumn 138, Issue 8, 2015, Pages 2370-2382

  Krohn, Markus ^a,b   Bracke, Alexander ^c   Avchalumov, Yosef ^b   Schumacher, Toni ^b   Hofrichter, Jacqueline ^b   Paarmann, Kristin ^a,b   Fröhlich, Christina ^b   Lange, Cathleen ^b   Brüning, Thomas ^a,b   Von Bohlen und Halbach, Oliver ^c   Pahnke, Jens ^a,b,d,e  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

Author keywords

ABCB1; ABCC1; Alzheimer's disease; amyloidosis; MCI; neprilysin

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; OLIGOMER; PROTEIN AGGREGATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYGDALOID NUCLEUS; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ASTROCYTOSIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DENDRITIC SPINE; ELECTROPHYSIOLOGY; ELEVATED PLUS MAZE TEST; ENVIRONMENTAL EXPOSURE; FEMALE; HIPPOCAMPUS; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOHISTOCHEMISTRY; LONG TERM POTENTIATION; MALE; MILD COGNITIVE IMPAIRMENT; MORPHOLOGY; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SURVIVAL RATE; SYNAPSE; TASK PERFORMANCE; WORKING MEMORY; Y-MAZE TEST; ANIMAL; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LONG-TERM POTENTIATION; MICE, KNOCKOUT; MILD COGNITIVE IMPAIRMENT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEPRILYSIN; NEURONS;

EID: 84940099409     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv137     Document Type: Article

References (60)

1. Becker M, Siems WE, Kluge R, Gembardt F, Schultheiss HP, Schirner M, et al. New function for an old enzyme: NEP deficient mice develop late-onset obesity. PloS One 2010; 5: e12793.
2. Bernstein HG, Holzl G, Dobrowolny H, Hildebrandt J, Trubner K, Krohn M, et al. Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary. Mech Ageing Dev 2014; 141-2: 12-21.
3. Carobrez AP, Bertoglio LJ. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 2005; 29: 1193-205.
4. Chaouloff F, Durand M, Mormede P. Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Behav Brain Res 1997; 85: 27-35.
5. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285-90.
6. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005; 8: 752-8.
7. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-13.
8. Desmond NL, Levy WB. Granule cell dendritic spine density in the rat hippocampus varies with spine shape and location. Neurosci Lett 1985; 54: 219-24.
9. Frohlich C, Paarmann K, Steffen J, Stenzel J, Krohn M, Heinze HJ, et al. Genomic background-related activation of microglia and reduced beta-amyloidosis in a mouse model of Alzheimer's disease. Eur J Microbiol Immunol 2013; 3: 21-7.
10. Gotz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9: 532-44.
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
12. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 2010; 77: 715-23.
13. Hofrichter J, Krohn M, Schumacher T, Lange C, Feistel B, Walbroel B, et al. Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr Alzheimer Res 2013; 10: 1057-69.
14. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Gen 1999; 29: 177-85.
15. Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA. Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J Neurochem 2008; 107: 557-69.
16. Huitron-Resendiz S, Sanchez-Alavez M, Gallegos R, Berg G, Crawford E, Giacchino JL, et al. Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in PDAPP mice. Brain Res 2002; 928: 126-37.
17. Iqbal K, Bolognin S, Wang X, Basurto-Islas G, Blanchard J, Tung YC. Animal models of the sporadic form of Alzheimer's disease: focus on the disease and not just the lesions. J Alzheimers Dis 2013; 37: 469-74.
18. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-2.
19. Jung JH, An K, Kwon OB, Kim HS, Kim JH. Pathway-specific alteration of synaptic plasticity in Tg2576 mice. Mol Cel 2011; 32: 197-201.
20. Kim WS, Li H, Ruberu K, Chan S, Elliott DA, Low JK, et al. Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci 2013; 33: 4387-94.
21. Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 2005; 280: 43224-35.
22. Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J, Steffen J, et al. Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Invest 2011; 121: 3924-31.
23. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, et al. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 2007; 17: 347-53.
24. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, et al. beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 2001; 76: 1121-8.
25. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. PNAS 1998; 95: 6448-53.
26. Lecanu L, Papadopoulos V. Modeling Alzheimer's disease with nontransgenic rat models. Alz Res Ther 2013; 5: 17.
27. Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, et al. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet 2003; 12: 2949-56.
28. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-7.
29. Lu B, Gerard NP, Kolakowski LF, Jr., Bozza M, Zurakowski D, Finco O, et al. Neutral endopeptidase modulation of septic shock. J Exp Med 1995; 181: 2271-5.
30. Madani R, Poirier R, Wolfer DP, Welzl H, Groscurth P, Lipp HP, et al. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res 2006; 84: 1871-8.
31. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330: 1774.
32. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 2004; 25: 663-74.
33. Pahnke J, Frohlich C, Krohn M, Schumacher T, Paarmann K. Impaired mitochondrial energy production and ABC transporter function-A crucial interconnection in dementing proteopathies of the brain. Mech Ageing Dev 2013; 134: 506-15.
34. Pahnke J, Frohlich C, Paarmann K, Krohn M, Bogdanovic N, Arsland D, et al. Cerebral ABC transporter: common mechanisms may modulate neurodegenerative diseases and depression in elderly subjects. Arch Med Res 2014a; 45: 738-43.
35. Pahnke J, Langer O, Krohn M. Alzheimer's and ABC transporters - new opportunities for diagnostics and treatment. Neurobiol Dis 2014b; 72 (Pt A): 54-60.
36. Pahnke J, Walker LC, Scheffler K, Krohn M. Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev 2009; 33: 1099-108.
37. Parnass Z, Tashiro A, Yuste R. Analysis of spine morphological plasticity in developing hippocampal pyramidal neurons. Hippocampus 2000; 10: 561-8.
38. Perez-Cruz C, Nolte MW, van Gaalen MM, Rustay NR, Termont A, Tanghe A, et al. Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J Neurosci 2011; 31: 3926-34.
39. Plucińska K, Crouch B, Koss D, Robinson L, Siebrecht M, Riedel G, et al. Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes. J Neurosci 2014; 34: 10710-28.
40. Radde R, Duma C, Goedert M, Jucker M. The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008; 35 (Suppl 1):S70-4.
41. Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, et al. Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol 2014; 76: 837-44.
42. Scheffler K, Krohn M, Dunkelmann T, Stenzel J, Miroux B, Ibrahim S, et al. Mitochondrial DNA polymorphisms specifically modify cerebral beta-amyloid proteostasis. Acta Neuropathol 2012; 124: 199-208.
43. Scheffler K, Stenzel J, Krohn M, Lange C, Hofrichter J, Schumacher T, et al. Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease. Curr Alzheimer Res 2011; 8: 781-8.
44. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. PNAS 1997; 94: 4028-33.
45. Schmidt A, Pahnke J. Efficient near-infrared in vivo imaging of amyoid-beta deposits in Alzheimer's disease mouse models. J Alzheimers Dis 2012; 30: 651-64.
46. Schumacher T, Krohn M, Hofrichter J, Lange C, Stenzel J, Steffen J, et al. ABC transporters B1, C1 and G2 differentially regulate neuroregeneration in mice. PloS One 2012; 7: e35613.
47. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106-13.
48. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489-99.
49. Sterniczuk R, Dyck RH, Laferla FM, Antle MC. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes. Brain Res 2010; 1348: 139-48.
50. Talarovicova A, Krskova L, Kiss A. Some assessments of the amygdala role in suprahypothalamic neuroendocrine regulation: a minireview. Endocr Regul 2007; 41: 155-62.
51. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol 2011; 95: 547-56.
52. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004; 1: 121-5.
53. Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, et al. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol 2000; 100: 36-42.
54. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101: 1172-84.
55. Walther T, Albrecht D, Becker M, Schubert M, Kouznetsova E, Wiesner B, et al. Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase. PloS One 2009; 4: e4590.
56. Webster CI, Burrell M, Olsson LL, Fowler SB, Digby S, Sandercock A, et al. Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease. PloS One 2014; 9: e104001.
57. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998; 153: 725-33.
58. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18: 253-66.
59. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997; 3: 1275-9.
60. Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med 2007; 8: 623-36.